Oncotelic Therapeutics (OTCQB: OTLC) reported its first-quarter 2026 financial results and provided a corporate update, underscoring continued advancement across its oncology, AI-enabled drug development, and advanced drug delivery initiatives. The company highlighted progress within its Sapu Nano joint venture and nose-to-brain CNS delivery platform, alongside maintaining the previously established fair value of approximately $388 million for its 45% ownership interest in GMP Biotechnology as of March 31, 2026.
The company is pursuing capital-efficient growth across its diversified biotechnology platform. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. Its drug pipeline is complemented by a robust portfolio of inventions created by CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.
Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond internal programs, the company licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that strengthens Oncotelic's position in oncology and rare disease therapeutics.
For more information on Oncotelic's latest updates, visit the company's newsroom at https://ibn.fm/OTLC. The full press release is available at https://ibn.fm/DTVsF.
